Lilly Drops a Bombshell at Morgan Stanley: Zepbound Now Holds 30%+ of New Starts in the Oral GLP-1 Category

Lilly USA president Ilya Yuffa told investors at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026 that 'Zepbound now has more than 30% share of new starts in the oral GLP-1 category,' and described the gain as 'a sharp improvement from earlier periods' and 'marked improvement in the last two months.' The phrasing is easy to misread: Zepbound is an injectable tirzepatide, not a pill, and Foundayo is the only oral GLP-1 Lilly sells. The most defensible interpretation is that of new patients who begin therapy on an oral incretin, a meaningfully larger share are now escalating to or starting alongside Lilly's tirzepatide franchise, with Foundayo positioned as the on-ramp and Zepbound as the destination. Lilly declined to commit to a December 2026 share target, signalling management sees further runway rather than a finished capture.

On raw Foundayo script counts, the launch still trails badly. Per IQVIA data cited by Citi and published in Fierce Pharma's weekly tracker on September 11, 2026, Foundayo hit 47.5K weekly prescriptions, up 8% week-over-week, versus the Wegovy pill at ~183K scripts. Jefferies tracked Foundayo's share of new prescriptions (NRx) in the oral obesity market at 21.5% in late August. Jefferies' full-year 2026 Foundayo sales estimate is now $1.6B, up from consensus of $1.2B after the Q2 print, while Lilly's Q2 itself booked only $98M, below the $104M consensus and a fraction of Novo Nordisk's ~$496M of oral Wegovy revenue. Read in isolation, Foundayo is the slower horse.

The Morgan Stanley disclosure changes the read. Management said new-patient starts on the oral incretin are converting to Zepbound at a >30% clip, and that 60-70% of Medicare Bridge enrollees are new-to-incretin patients rather than switches. Two of three new patient starts now flow into Lilly's franchise in some form. Foundayo's job is not to defeat the Wegovy pill on pill volume; it is to widen the funnel and hand the patient to Zepbound once the patient is titrated, motivated, and pre-approved. That makes the $98M Q2 print a deliberate down-payment on a much larger tirzepatide annuity.

Two trajectories are running in parallel. On the pill-only scoreboard, Novo Nordisk is winning: oral Wegovy logged ~$496M in Q2 2026, more than 5x Foundayo's $98M, and reached 5M cumulative U.S. prescriptions in roughly nine months. On the franchise scoreboard, Eli Lilly is winning by a wider margin: Q2 2026 Zepbound sales hit $4.93B (+46% YoY) and Mounjaro $9.94B (+91%), with the two GLP-1/GIP drugs combining for ~$14.9B or roughly 65% of Lilly's total revenue. Lilly's U.S. incretin share rose to 60.9% in Q2 2026 from 60.1% in Q1, while Novo Nordisk sat at 38.8%. Lilly's Q2 gross margin was 85.8%, and management raised full-year 2026 revenue guidance to $85.0B-$87.0B (from $82.0B-$85.0B), with non-GAAP EPS guidance to $35.50-$36.50.

The reason the gap is durable is the conversion funnel Yuffa pointed to. Lilly's ATTAIN-MAINTAIN trial showed Zepbound patients who switched to Foundayo regained more weight than Wegovy patients who switched to Foundayo, evidence that pill-form therapy alone rarely delivers Zepbound-class efficacy. The clinical pathway therefore runs: Foundayo initiates, Zepbound titrates, Mounjaro retains. The pill is not the product; the patient is the product. That logic reframes the Morgan Stanley 30% number: Lilly is signalling it can monetise a Foundayo start twice — once on the prescription and once on the conversion — while Novo Nordisk's Wegovy pill mostly converts inside its own semaglutide franchise.

Yuffa put the access gap squarely on the table. Commercial insurance coverage for obesity treatments is 'about 50%' today, even after CVS Caremark added Foundayo to its formulary on June 1, 2026 and agreed to restore Zepbound as a preferred option on October 1, 2026. Lilly's Medicare Bridge program has reached ~600,000 beneficiaries in early months against ~20M eligible under the program's clinical criteria. If commercial coverage crosses from 50% to 60-70%, even the lower estimate of 30% new-start conversion implies a Foundayo-to-Zepbound cascade worth tens of billions of incremental cumulative revenue through 2030.

Lilly built Foundayo's supply chain to support a blockbuster outcome even though Q2 sales came in light. As of December 31, 2025, Lilly had ~$1.5B in pre-launch orforglipron inventory disclosed in its 10-K, an aggressive posture aimed at avoiding the tirzepatide shortages of 2023-2024. In March 2026 Lilly announced a $3B, decade-long build-out of Chinese manufacturing for oral solids. In July 2026 Eli Lilly and National Resilience announced a $750M joint investment in U.S. pharmaceutical manufacturing. The Houston Generation Park API campus, announced September 2025 at $6.5B, broke ground in mid-2026 with 615 planned full-time jobs. Foundayo itself has launched in the UAE and UK, won approvals in Saudi Arabia and Mexico, and is targeted for >40 markets by 2027.

Three things to watch. First, Foundayo NRx share: Jefferies pegged it at 21.5% in late August; if Q4 IQVIA reads above 30% on the pill-only basis (not the broader Zepbound figure Lilly disclosed today), the new Morgan Stanley number will look vindicated. Second, the ATTAIN-4 cardiovascular readout, which would extend Foundayo's label beyond obesity and into the cardiovascular risk-reduction territory that already differentiates Wegovy. Third, oral tirzepatide: Lilly has not announced a pill form of tirzepatide, but a positive Foundayo-plus-Zepbound maintenance story makes a future oral dual-agonist economically obvious.